Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

MedXY Editorial Team•Oct 6, 2025•Cardiology

Long-term beta-blocker therapy after acute myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF ≥50%) shows no significant reduction in risk of death or recurrent MI compared to no beta-blocker use.
Discontinuation of beta-blockers within 12 months after acute coronary syndrome (ACS) in patients with LVEF ≥40% did not increase major adverse cardiovascular events (MACE), with a potential differential risk in STEMI versus NSTEMI subgroups.
Meta-analysis indicates declining mortality benefits of beta-blockers post-MI over time, particularly beyond the first year and in patients with preserved EF, suggesting possible detrimental effects with prolonged use in this population.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Long-term beta-blocker therapy after acute myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF ≥50%) shows no significant reduction in risk of death or recurrent MI compared to no beta-blocker use.
Discontinuation of beta-blockers within 12 months after acute coronary syndrome (ACS) in patients with LVEF ≥40% did not increase major adverse cardiovascular events (MACE), with a potential differential risk in STEMI versus NSTEMI subgroups.
Meta-analysis indicates declining mortality benefits of beta-blockers post-MI over time, particularly beyond the first year and in patients with preserved EF, suggesting possible detrimental effects with prolonged use in this population.